Grace Therapeutics, Inc.
GRCE
$4.44
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.31% | 72.64% | -28.47% | 120.09% | -73.78% |
| Total Depreciation and Amortization | 50.00% | -100.00% | 100.00% | 100.00% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -79.81% | -20.77% | 141.95% | -1,045.31% | 9,262.50% |
| Change in Net Operating Assets | 90.36% | -586.63% | -14.54% | -109.38% | -237.35% |
| Cash from Operations | 45.81% | 25.86% | 49.92% | -41.48% | -117.49% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | 100.23% |
| Cash from Investing | -- | -- | -- | -100.00% | 100.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 9,158.64% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -496.91% | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.15% | 25.86% | 41.07% | 148.39% | 51.46% |